The Simoldes Group will donate 1.6 million euros to the Champalimaud Foundation to support the development of a breast cancer research program, the foundation announced this Monday.
In a statement, Champalimaud states that the donation “It will be essential to drive significant advances in the fight against this disease.”
The funding is intended to support the development of a program dedicated to “improve quality of life and survival” of patients, using cutting-edge technologies.
“The integration of new technologies with clinical practice is essential to develop more effective and personalized treatments, directly benefiting patients,” highlights the foundation.
Through the donation, research projects in the field of quality of life and physical exercise, digital surgery, artificial intelligence applied to breast cancer surgeryand registration and development of alliances with other entities.
Source: Observadora
